Skip to main content
. 2018 Oct 15;8:15229. doi: 10.1038/s41598-018-33449-0

Figure 3.

Figure 3

Validation of differential expression for selected metabolite features. (a) CSF metabolite profile of N-acetylneuraminic acid and Unknown 1–6 including Unknown 1 adduct and Unknown 1 fragment for CLN2 and control individuals in ANPneg mode, except for unknown 6 which was only detected in the test cohort with positive ion monitoring (absence of this feature in the validation set (b)). (b) Abundance values of the metabolites of the validation set were normalized by the average fold change of B12, B13, B14, B15, B17, B20 and B26, as quantified on data acquisition days for both the initial case analysis and validation study cases.